Please assess the completion status of the following clinical trial:

Trial Title: Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Metastatic breast cancer (Stage IV)~2. Histologically confirmed estrogen receptor positive disease~3. Female~4. Serum 25(OH) \<30 ng/ml~5. Age ≥ 18 years~6. Pre or post-menopausal~7. ECOG Performance status 0-2~8. Adequate organ function as defined as GFR\> 30 mls/min and serum calcium ≤ 10.4 mg/dl~9. Any race/ethnicity~10. English speaking~11. No changes to MBC treatments within 30 days of enrollment and/or deemed clinically stable by their treating physician~12. Willingness to sign a written informed consent and complete questionnaires~13. Cease ingestion of vitamin D supplementation not study related~Exclusion Criteria:~1. Women with Stage I-III breast cancer~2. Serum 25(OH)D levels ≥ 30 ng/ml~3. Untreated CNS involvement~4. History of kidney stones~5. History of renal failure~6. History of hyperparathyroidism~7. History of hypersensitivity to vitamin D~8. Non-English speaking~9. Currently pregnant or lactating, or anticipating pregnancy~10. Unwilling to cease ingestion of calcium supplements (\>1000 mg/d)~11. Unwilling or unable to complete informed consent or study questionnaires~12. Psychiatric or other clinical conditions that preclude study compliance~13. Other important medical or safety considerations at the discretion of the investigator and/or study physician, including non-compliance with the study therapy or other activities

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cholecalciferol (Type: EXPERIMENTAL): All participants will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
- Vitamin D sufficient (Type: NO_INTERVENTION): All participants were ineligible for the intervention due to sufficient serum 25(OH)D levels at screening/baseline.

Based on this trial design, predict the completion outcome and termination type (if applicable).